Free Newsletter
EU approves Shering-Plough's Bridion
Free newsletter via e-mail
Tools
The European Union approved Shering-Plough's Bridion (sugammadex) in an injection form for the purposes of reversing neuromuscular blockade during general anesthesia more rapidly. This will be the first product approval since Schering-Plough joined forces with Organon BioSciences. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: